查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
藥物發現和下一代治療中的合成生物學 (SynBio)
市場調查報告書
商品編碼
1308048

藥物發現和下一代治療中的合成生物學 (SynBio)

Synthetic Biology (SynBio) in Drug Discovery and Next-generation Therapeutics
出版日期: | 出版商: Frost & Sullivan | 英文 71 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

合成生物學（SynBio）顛覆性技術的進步，以培育繁榮的利益相關者生態系統並加速生物製藥的發展

過去二十年，合成生物學領域取得了長足發展，重大技術創新提供了新的機遇和巨大的成長潛力。合成生物學技術的進步徹底改變了藥物發現和療法開發，加速了新藥物靶點的識別、高通量化合物篩選並促進了藥物發現。對治療學的貢獻導致了更永續和穩定的治療方法的設計和開發。新的、有前景的合成生物學工具，例如基因電路和 CRISPR 系統，能夠開發下一代細胞療法、抗體和具有治療活性的人造生物體。下一代療法的興起可能會在未來幾年變得突出，特別是在利用合成生物學開發 CAR-T 細胞免疫療法方面，因為它具有精確和個性化的能力。

Frost & Sullivan 指出，隨著世界走向精準醫療，新興的合成生物學生態系統跨地區發展。學術界、初創新興企業大力研究和開發針對癌症、傳染病和罕見疾病的合成生物學驅動療法。

合成生物學平台也廣泛用於治療藥物的生物製造，使公司能夠根據商業需求經濟高效地擴展治療藥物。技術發展將推動合成生物學工具在世界各地的採用，推動融資生態系統並帶來高成長機會。

本報告提供的資訊包括：

  • 成長促進因素和抑制因素（2023-2027）
  • 支持藥物發現的合成生物學技術的發展
  • 合成生物學治療劑開發中的關鍵問題及對策
  • 全球潛在市場進入者

目錄

戰略問題

  • 為什麼成長如此困難？戰略要務 8 (TM)：成長的障礙
  • The Strategic Imperative 8 (TM)
  • 合成生物學在藥物發現和治療行業中的戰略問題：三大影響
  • 透過成長機會加速成長管道引擎 (TM)
  • 調查方法

成長機會分析

  • 合成生物學成為研究和開發中有前途的工具
  • 成長促進因素
  • 生長抑制因素
  • 分析範圍
  • 區隔
  • 技術成熟度
  • 新興企業（2020-2022）
  • 趨勢
  • 主要發現

藥物發現中的技術創新和研發場景

  • 透過遺傳電路和 CRISPR 系統識別新靶標
  • 加速先進療法設計和開發的合成生物學平台
  • 合成生物學在藥物發現管道中的作用
  • 透過合成生物學驅動的方法進行靶點識別和藥物分子篩選
  • 先進的 CRISPR 系統改善藥物靶點篩選
  • 複雜的基因迴路作為藥物發現的即時監測工具
  • 利用先進的合成電路平台實現高通量藥物篩选和選擇
  • 利用器官晶片和類器官系統加速合成生物學驅動的藥物發現
  • 改進合成生物學工具的設計以應對藥物發現挑戰
  • 合成生物驅動的藥物發現公司網絡不斷擴大

治療藥物創新及研發場景

  • 使用合成生物學工具開發下一代療法
  • 使用合成生物學工具實現受控治療反應
  • 合成生物學平台的引進將改變全球疾病的治療
  • 利用合成生物學工具開發先進的療法和疫苗
  • 行業參與者使用合成生物學工具開發先進的療法和疫苗
  • 利用合成生物學工具開發智慧細胞療法
  • 邏輯閘：透過精確的開關機制提高工程細胞的活性
  • 研發：致力於開發合適的合成生物學電路/系統
  • 研究人員利用基因電路開發可編程醫學
  • 用作治療劑的多功能底盤生物體：改善可擴展性和藥物輸送
  • 綜合工程微生物療法的開發
  • 作為活體治療的工程微生物

促進藥物發現和治療藥物生產規模擴大的合成生物學工具

  • 透過生物感測器識別藥物靶點並敏感地釋放治療劑
  • 利用基因電路進行治療藥物的無細胞生物製造
  • 無細胞生物製造系統的用途和需求不斷擴大

資金和合作夥伴關係

  • 促進全球籌款工作，支持合成生物學平台的發展
  • 目的是提高合成生物學平台能力的併購數量不斷增加
  • 擴大與合成生物學治療開發商和製藥公司的合作夥伴關係
  • 利用世界合成生物學平台加速藥物發現和治療

未來

  • 合成生物學治療的差距分析
  • 基於基因迴路釋放療法的生物細胞療法

成長機會宇宙

  • 成長機會1：利用合成基因迴路提高CAR-T細胞療法的長期療效
  • 成長機會2：推動協同研究，打造融合合成生物學平台
  • 成長機會3：簡化在治療中使用合成基因迴路的監管途徑

附錄

  • 利用先進的合成生物學 DBTL 循環加速藥物發現

下一步

  • 下一步
  • 為什麼選擇 Frost & Sullivan？為什麼選擇現在？
  • 免責聲明
簡介目錄
Product Code: DAA1

Disruptive Technology Advances in SynBio Foster a Thriving Stakeholder Ecosystem and Accelerate Biopharma Developments

The SynBio field has evolved well over the past two decades, with significant technology disruptions leading to new opportunities and remarkable growth potential. Advances in SynBio technologies have transformed drug discovery and therapeutics development, accelerating the identification of novel drug targets and high-throughput compound screening and easing drug discovery. Its contribution to therapeutics has resulted in the design and development of more sustainable and stable therapies. Emerging and promising SynBio tools, such as gene circuits and CRISPR systems, enable the development of next-generation cell therapies, antibodies, and engineered organisms with therapeutic effects. The rise in next-generation therapeutics will be evident in the coming years, especially in developing CAR-T cell immunotherapy using Synbio, as it can provide accuracy and personalization.

Frost & Sullivan notes a rise in the SynBio start-up ecosystem across regions as the world moves toward precision medicine. Intense R&D efforts are ongoing in academia, start-ups, and big pharmaceutical companies toward developing SynBio-driven therapies for cancer, infectious diseases, and rare diseases.

Therapeutics biomanufacturing also widely uses SynBio platforms, allowing companies to scale therapeutics based on commercial requirements cost-efficiently. Technology developments will boost the global adoption of SynBio tools, encourage the funding ecosystems, and move toward high-growth opportunities.

Information provided in this report includes the following:

  • Growth drivers and restraints (2023-2027)
  • Developments in SynBio technologies supporting drug discovery
  • Critical challenges in developing SynBio therapeutics and the steps taken to address them
  • Global market participants with potential

Table of Contents

Strategic Imperatives

  • Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on SynBio in the Drug Discovery and Therapeutics Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™
  • Research Methodology

Growth Opportunity Analysis

  • SynBio Emerges as a Promising Tool in R&D
  • Growth Drivers
  • Growth Restraints
  • Scope of Analysis
  • Segmentation
  • Technology Maturity
  • Emerging Companies, 2020-2022
  • Trends
  • Key Findings

Technology Innovations and R&D Scenario in Drug Discovery

  • Gene Circuits and CRISPR Systems Identify Novel Targets
  • SynBio Platforms Accelerate the Design and Development of Advanced Therapeutics
  • Role of SynBio Approaches in the Drug Discovery Pipeline
  • Target Identification and Drug Molecule Screening Using SynBio-driven Approaches
  • Advanced CRISPR Systems for Improved Drug Target Screening
  • Complex Gene Circuits Act as a Tool for Real-time Monitoring of Drug Discovery
  • Advanced Synthetic Circuit Platforms Enable High-throughput Drug Screening and Selection
  • Organ-on-a-chip and Organoid Systems Speed SynBio-driven Drug Discovery
  • Improving the Design of SynBio Tools to Address Challenges in Drug Discovery
  • The Growing Network of SynBio-driven Drug Discovery Companies

Technology Innovations and R&D Scenario in Therapeutics

  • Developing Next-generation Therapeutics Using SynBio Tools
  • Controlled Therapeutic Responses Achieved Using SynBio Tools
  • SynBio Platform Adoption Can Transform Global Disease Treatment
  • Developing Advanced Therapeutics and Vaccines with SynBio Tools
  • Industry Players Developing Advanced Therapeutics and Vaccines Using SynBio Tools
  • SynBio Tools Enable the Development of Smart Cell Therapies
  • Logic Gates Improve the Engineered Cellular Activity with a Precise Switch On/Off Mechanism
  • R&D Efforts Focus on Developing Suitable SynBio Circuit/System
  • R&D Players Developing Programmable Medicine Using Gene Circuits
  • Multifunctional Chassis Organisms Used as Therapeutics Improve Scalability and Delivery
  • Developing Synthetically Engineered Microbiome Therapies
  • Engineered Microorganisms n Functioning as Live Therapeutics

SynBio Tools Facilitating Drug Discovery and Scaling Up Therapeutic Production

  • Biosensors Identify Drug Targets and Release Therapeutics with Sensitivity
  • Cell-free Biomanufacturing of Therapeutics Using Gene Circuits
  • Growing Applications and Demand for Cell-free Biomanufacturing Systems

Funding and Partnerships Landscape

  • Encouraging Global Funding Activities to Boost the Growth f SynBio Platforms
  • Growing Mergers & Acquisitions o Improve SynBio Platform Capabilities
  • Growing Partnerships Between SynBio Therapy Developers and Pharmaceutical Companies
  • Global SynBioPlatforms or Accelerated Drug Discovery and Therapeutics

The Road Ahead

  • Gap Analysis for SynBio-based Therapies
  • Living ell Therapeutics to Release Therapies Based on Gene Circuits

Growth Opportunity Universe

  • Growth Opportunity 1: Improve the Long-term Efficiency of CAR-T Cell Therapies Using Synthetic Gene Circuits
  • Growth Opportunity 2: Foster Collaborations to Build Convergent SynBio Platforms
  • Growth Opportunity 3: Streamline Regulatory Pathways for Using Synthetic Gene Circuits in Therapeutics

Appendix

  • Advanced SynBio DBTL Cycle Speeds Drug Discovery

Next Steps

  • Your Next Steps
  • Why Frost, Why Now?
  • Legal Disclaimer